The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant immunotherapy and nonoperative management of dMMR gastroesophageal adenocarcinoma (GEA): A retrospective case series.
 
Oudai Sahvan
No Relationships to Disclose
 
Fares Jamal
No Relationships to Disclose
 
Mitesh Borad
Consulting or Advisory Role - BJ Bioscience; Genentech; Imvax; Kriya Therapeutics; Lynx Group; Merck; Senti Biosciences; Tempus; Zymeworks
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Basilea (Inst); Biond Biologics (Inst); Celgene (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Merck Serono (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Qurient (Inst); RedHill Biopharma (Inst); Relay Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Taiho Pharmaceutical (Inst); ZielBio (Inst)
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Christina Wu
Honoraria - Cancer Treament Centers of America; Medscape
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Exelixis; Natera; Natera; Nova Research Company; Pfizer; Seagen
Research Funding - HUTCHMED; Pfizer; Sirnaomics (Inst); Sumitomo Pharma (Inst)
 
Daniel Ahn
Stock and Other Ownership Interests - Natera
Consulting or Advisory Role - Advanced Accelerator Applications; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genentech/Roche; Incyte; Incyte; Novartis
Research Funding - AstraZeneca; Bayer
 
Mohamad Sonbol
Honoraria - Novartis
Research Funding - Lilly (Inst); Taiho Oncology (Inst)